Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.…
OXB confirms partnership with Aura Biosciences supporting Phase 3 development and future commercial supply of lead oncology candidate
Aura Biosciences (NASDAQ: AURA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 113 employees.
The shares were at 6.870 USD on 20 November 2026, up 28.4% over 52 weeks. Its 52-week range is 4.730 USD to 9.535 USD: the price is 27.9% below the high and 45.2% above the low.
Its market capitalisation is 714.99M USD.
Aura Biosciences reports return on equity of -77.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 281.06M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 16.60 USD is 141.6% above the current price. The next earnings report is expected on 29 March 2027.